KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal. PMID 39478672 · J Infect Dis · 2025-Jun-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis. PMID 40465504 · J Drugs Dermatol · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial. PMID 40452026 · BMC Cancer · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of a community health advisor colorectal cancer screening educational intervention on stool test completion in an African American primary care patient population: a pragmatic randomized controlled trial. PMID 40450376 · BMC Glob Public Health · 2025-Jun-01 Study is a randomized controlled trial in oncology (colorectal cancer screening) with human subjects and reports primary results. However, it is excluded because: 1) The intervention is a non-drug educational/community health advisor program, not a drug-containing intervention. 2) The primary efficacy endpoint is the proportion completing stool test at 12 months (a binary outcome), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, nor are Kaplan-Meier curves or hazard ratios reported. The trial registration number is provided but no phase is explicitly stated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized controlled trial reporting guidelines should be updated to include information on subsequent treatments. PMID 40440214 · Cancer · 2025-Jun-01 The record is an editorial/commentary advocating for updated reporting guidelines, not an original report of a randomized trial with results. It discusses oncology trials and time-to-event endpoints (e.g., PFS2) but does not present primary or secondary efficacy data from a specific Phase III or definitive trial. It lacks explicit human trial phase information and drug intervention details for a specific study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist. PMID 40423237 · Endocr Connect · 2025-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma. PMID 40338596 · JAMA Ophthalmol · 2025-Jun-01 The record describes a phase 3b case series study characterizing ocular side effects of belantamab mafodotin in multiple myeloma patients. While it is an oncology study with a drug intervention in humans and phase 3/3b, it is non-randomized and its primary endpoint is pathologic characterization of corneal changes, not a time-to-event efficacy outcome. Therefore, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. PMID 40257755 · JAMA Intern Med · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial. PMID 40244574 · JAMA Oncol · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections. PMID 40233296 · Pediatr Infect Dis J · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial. PMID 40136309 · JAMA Cardiol · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. PMID 40117446 · Anesthesiology · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
VERY EARLY USE OF ESMOLOL IN HYPERKINETIC SEPTIC SHOCK PATIENTS WITH PERSISTENT TACHYCARDIA: A RANDOMIZED CONTROLLED PILOT STUDY. PMID 40101954 · Shock · 2025-Jun-01 The record describes a randomized controlled pilot study in septic shock (non-oncology) evaluating esmolol for heart rate control. It is not a trial of human malignant neoplasm, does not report a Phase III/IIIb or Phase II/III trial, and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome. PMID 40051199 · J Clin Sleep Med · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. PMID 40042880 · JAMA Cardiol · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial. PMID 40037556 · Rheumatology (Oxford) · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Abatacept and the risk of malignancy: a meta-analysis across disease indications. PMID 39992258 · Rheumatology (Oxford) · 2025-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab. PMID 39985454 · Rheumatology (Oxford) · 2025-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial. PMID 39972543 · J Acquir Immune Defic Syndr · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Censoring Analysis of the INvestigating VorasiDenib In GliOma (INDIGO) Phase III Randomized Controlled Trial. PMID 39950862 · Am J Clin Oncol · 2025-Jun-01 The title indicates a Phase III randomized trial in glioma (oncology) with a drug (vorasidenib). However, the title alone ('Censoring Analysis of...') does not provide evidence of a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) or a primary/original result report. The abstract is empty, offering no further data. Human subject participation and the original result status cannot be confirmed from the available metadata. Without explicit evidence of a time-to-event endpoint or a formal efficacy result report, eligibility cannot be established.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial. PMID 39922319 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer. PMID 39922318 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. PMID 39918968 · Rheumatology (Oxford) · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial. PMID 39914555 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 The study is a Phase III randomized trial with time-to-event endpoints in oncology, but the intervention is radiation therapy (hypofractionated vs. conventional), not a drug-containing intervention as required by the criteria.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT). PMID 39862898 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 The trial compares radiation therapy techniques (standard vs. dose-painted RT), not a drug intervention. While concurrent chemotherapy is given in both arms, it is standard background therapy, not the tested drug intervention. The phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies. PMID 39798135 · Rheumatology (Oxford) · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase. PMID 39792028 · Rheumatology (Oxford) · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk. PMID 39657237 · Rheumatology (Oxford) · 2025-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of thrombolysis type on the efficacy of aspiration versus stent retriever first line thrombectomy: results from the AcT trial. PMID 39379314 · J Neurointerv Surg · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and efficacy of adjunctive intra-arterial antithrombotic therapy during endovascular thrombectomy for acute ischemic stroke: a systematic review and meta-analysis. PMID 38253378 · J Neurointerv Surg · 2025-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma. PMID 41646284 · ESMO Gastrointest Oncol · 2025-Jun The record describes a secondary benefit-risk assessment analysis of a Phase III randomized trial, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213. PMID 41646270 · ESMO Gastrointest Oncol · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[Clinical study on the effect of glycosaminoglycans on vascular endothelial glycocalyx in sepsis]. PMID 40820527 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-Jun The study is a randomized trial in sepsis patients, which is not an oncology indication. While it involves a drug intervention (glycosaminoglycans), it does not assess a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) in human malignant neoplasms. It measures biomarker levels, clinical scores, and short-term mortality, not Kaplan-Meier or hazard ratio data for cancer outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Fludrocortisone to treat patients with aneurysmal subarachnoid haemorrhage: Protocol for an international, phase 3, randomised, placebo-controlled, multicentre trial. PMID 40677678 · Crit Care Resusc · 2025-Jun 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. PMID 40620871 · Prostate Int · 2025-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3 Multicenter, Double-Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis. PMID 40620511 · Aging Med (Milton) · 2025-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Once-Weekly Trelagliptin As Compared to Twice-Daily Vildagliptin in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Phase 3, Non-inferiority Clinical Trial. PMID 40605903 · Cureus · 2025-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The efficacy of mosapride on recovery of intestinal motility after elective colorectal cancer surgery: a randomized controlled trial. PMID 40598989 · Ann Coloproctol · 2025-Jun Study is an oncology RCT with a drug intervention and reports primary results, but its primary efficacy endpoints (time to first bowel movement, time to flatus) are not time-to-event endpoints in the required sense (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Primary Cytoreductive Surgery Versus Neoadjuvant Chemotherapy Followed by Surgery in Patients with Advanced Primary Epithelial Ovarian Cancer in Low Resources Setting: A Randomized Clinical Trial. PMID 40584804 · J Obstet Gynaecol India · 2025-Jun The study is a randomized, oncology, human trial with drug intervention and time-to-event endpoints. However, the trial phase is not explicitly stated in the abstract or metadata as Phase III/IIIb or Phase II/III. The 'METHOD' section mentions a randomized controlled trial but does not specify the phase. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information meeting the inclusion criteria, the record is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy for Very Low-Lying Clinical T3 Rectal Cancer: The NAIR Phase 2/3 Randomized Clinical Trial. PMID 40557347 · Ann Surg Open · 2025-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 7 Panel · risk visible
A Randomized Open-Label, Noninferiority, Phase 3, Multicenter, Controlled Trial to Compare Laparoscopic Surgery With Open Surgery for Symptomatic, Noncurable Stage IV Colorectal Cancer (JCOG1107). PMID 40557341 · Ann Surg Open · 2025-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Demographics and Immunotherapy Efficacy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Phase III Clinical Trials. PMID 40547956 · Liver Cancer · 2025-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease. PMID 40545559 · Alzheimers Dement · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Early intensive blood pressure management after endovascular treatment in ischaemic stroke (IDENTIFY): a multicentre, open-label, blinded-endpoint, randomised controlled trial. PMID 40538518 · Lancet Reg Health West Pac · 2025-Jun The study is a randomised controlled trial in acute ischaemic stroke (non-oncology), with a primary endpoint of functional outcome at 90 days (not a time-to-event efficacy endpoint like OS, PFS, etc.). It evaluates intensive blood pressure management (a physiological intervention), not a drug-containing intervention. Therefore, it does not meet multiple core eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. PMID 40528576 · Curr Med Res Opin · 2025-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
A Randomized Trial of Nutrition and Exercise Treatment in Patients With Pancreatic and Non-Small Cell Lung Cancer (NEXTAC-TWO). PMID 40522817 · J Cachexia Sarcopenia Muscle · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies. PMID 40515823 · Ann Hematol · 2025-Jun The study is a Phase III randomized trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH). PNH is not classified as a human malignant neoplasm (cancer). Furthermore, the primary endpoint is patient-reported outcomes (PROs) related to quality of life and fatigue, not a time-to-event efficacy endpoint such as OS, PFS, or DFS. Therefore, it does not meet the oncology cohort eligibility criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eflornithine for the Chemoprevention of Luminal Gastrointestinal Neoplasms: A Systematic Review. PMID 40503186 · Gastroenterology Res · 2025-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies. PMID 40486134 · JHEP Rep · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate-Adaptive Randomization. PMID 40481756 · Stat Med · 2025-Jun The record is a methodological study on sample size and interim analysis strategies for survival trials, not a report of a clinical trial's efficacy results. While it mentions oncology (lung neoplasms) and uses survival analysis concepts, it does not present original results from a randomized trial with a drug intervention and a primary time-to-event efficacy endpoint. It lacks explicit mention of a Phase III or definitive Phase II/III design, a drug-containing intervention arm, and a primary time-to-event endpoint like OS or PFS with Kaplan-Meier or HR data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -